Sign in
RZLT Stock Price, Chart, Stats & News
Rezolute, Inc.
Save
Rezolute, Inc. (RZLT) does not currently pay a dividend.
490.13M
Market cap
–
Current P/E
–
Forward P/E
RZLT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -60.76% |
ROE | -64.81% |
D/E | 0.01x |
Interest coverage ratio | – |
RZLT valuation
P/E | – |
P/S | – |
P/B | 2.42x |
P/CF | -4.02x |
P/FCF | -3.71x |
P/OCF | -4.02x |
PEG | -0.04x |
EV multiple | -3.36x |
About
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Similar securities
Based on sector and market capitalization
Report issue